The Covid-19 pandemic is a global health emergency. Vaccines and drugs to prevent and manage infection and disease are urgently needed. Repurposing of existing drugs with known safety profiles represents a pragmatic approach to rapidly identify and develop new therapies for Covid-19.
The DRECOR project team makes use of this approach. Coordinated by the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, in total six Fraunhofer Insitutes and a Fraunhofer Project Center – among them the Fraunhofer Institute for Cell Therapy and Immunology IZI – work together in the framework of DRECOR.
The project partners aim at generating candidate molecules formulated for inhalative administration or systemic administration targeting the airways. They will develop a device prototype for clinical development. Moreover, the DRECOR team will provide sophisticated models and test systems that can be applied to other projects and indication areas. Fraunhofer IZI will contribute its expertise in the in vivo efficacy testing of suitable drug candidates. At the end a multidisciplinary drug formulation and delivery network and process will be established within DRECOR, improving our preparedness for future pandemics.